Catalyst Pharmaceuticals (CPRX) Stock Rating Upgraded by BidaskClub

Share on StockTwits

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald started coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, September 20th. They set an “overweight” rating and a $8.00 target price on the stock. Piper Jaffray Companies initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Friday, September 7th. They issued an “overweight” rating and a $5.00 price target on the stock. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Monday, August 13th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, August 9th. Finally, ValuEngine downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $5.61.

CPRX opened at $3.31 on Thursday. Catalyst Pharmaceuticals has a fifty-two week low of $2.18 and a fifty-two week high of $4.51. The company has a market cap of $357.05 million, a price-to-earnings ratio of -15.76 and a beta of 1.46.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. On average, equities analysts predict that Catalyst Pharmaceuticals will post -0.29 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of CPRX. BlackRock Inc. lifted its position in shares of Catalyst Pharmaceuticals by 29.0% in the 2nd quarter. BlackRock Inc. now owns 6,059,627 shares of the biopharmaceutical company’s stock worth $18,905,000 after purchasing an additional 1,361,096 shares during the period. GSA Capital Partners LLP lifted its position in shares of Catalyst Pharmaceuticals by 295.7% in the 2nd quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock worth $1,187,000 after purchasing an additional 284,409 shares during the period. Millennium Management LLC lifted its position in shares of Catalyst Pharmaceuticals by 16.5% in the 2nd quarter. Millennium Management LLC now owns 1,610,176 shares of the biopharmaceutical company’s stock worth $5,024,000 after purchasing an additional 227,918 shares during the period. Northern Trust Corp lifted its position in shares of Catalyst Pharmaceuticals by 22.5% during the 1st quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock valued at $2,414,000 after acquiring an additional 185,639 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $476,000. Hedge funds and other institutional investors own 51.49% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Further Reading: How to Invest in an Index Fund

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Horizonte Minerals  Hits New 1-Year Low at $0.03
Horizonte Minerals Hits New 1-Year Low at $0.03
Avivagen  Reaches New 12-Month Low at $0.42
Avivagen Reaches New 12-Month Low at $0.42
FrankyWillCoin  Price Reaches $0.0034 on Exchanges
FrankyWillCoin Price Reaches $0.0034 on Exchanges
Bitcoin Zero Price Tops $0.0239
Bitcoin Zero Price Tops $0.0239
Physicians Realty Trust  Expected to Post Quarterly Sales of $103.44 Million
Physicians Realty Trust Expected to Post Quarterly Sales of $103.44 Million
Analysts Set $17.55 Target Price for GreenTree Hospitality Group Ltd –
Analysts Set $17.55 Target Price for GreenTree Hospitality Group Ltd –


© 2006-2018 Ticker Report